Protagenic Therapeutics Stock Alpha and Beta Analysis
| PTIXW Stock | USD 0.01 0 11.11% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Protagenic Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Protagenic Therapeutics over a specified time horizon. Remember, high Protagenic Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Protagenic Therapeutics' market risk premium analysis include:
Beta (2.97) | Alpha 1.61 | Risk 262.9 | Sharpe Ratio 0.22 | Expected Return 57.67 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Protagenic |
Protagenic Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Protagenic Therapeutics market risk premium is the additional return an investor will receive from holding Protagenic Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Protagenic Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Protagenic Therapeutics' performance over market.| α | 1.61 | β | -2.97 |
Protagenic Therapeutics Fundamentals Vs Peers
Comparing Protagenic Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Protagenic Therapeutics' direct or indirect competition across all of the common fundamentals between Protagenic Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Protagenic Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Protagenic Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Protagenic Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Protagenic Therapeutics to competition |
| Fundamentals | Protagenic Therapeutics | Peer Average |
| Return On Equity | -2.06 | -0.31 |
| Return On Asset | -0.9 | -0.14 |
| EBITDA | (4.5 M) | 3.9 B |
| Net Income | (5 M) | 570.98 M |
| Cash And Equivalents | 671.09 K | 2.7 B |
| Cash Per Share | 0.06 X | 5.01 X |
| Total Debt | 655.25 K | 5.32 B |
Protagenic Therapeutics Opportunities
Protagenic Therapeutics Return and Market Media
The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | Acquisition by Garo Armen of 500000 shares of Protagenic Therapeutics at 1.25 subject to Rule 16b-3 | 04/29/2024 |
2 | Acquisition by Robert Stein of 200000 shares of Protagenic Therapeutics at 1.75 subject to Rule 16b-3 | 05/09/2024 |
3 | Acquisition by Musci Raymond of tradable shares of Protagenic Therapeutics at 2.0 subject to Rule 16b-3 | 05/13/2024 |
4 | Acquisition by Brilliant Digital Entertainment Inc of 758621 shares of Protagenic Therapeutics at 2.9 subject to Rule 16b-3 | 07/15/2024 |
5 | Disposition of 75000 shares by Ekizian Gregory of Protagenic Therapeutics at 1.0 subject to Rule 16b-3 | 09/26/2024 |
About Protagenic Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Protagenic or other stocks. Alpha measures the amount that position in Protagenic Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.25 | 0.24 | Days Of Inventory On Hand | 269.53 | 275.1 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protagenic Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protagenic Therapeutics' short interest history, or implied volatility extrapolated from Protagenic Therapeutics options trading.
Build Portfolio with Protagenic Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.